Mark Noviski
Seminars
Wednesday 29th October 2025
PROteolysis TArgeting Chimera (PROTAC) Degrader Molecules Selectively Clear Proteins that Cause Neurological Diseases
2:30 pm
- CNS malignancies and inflammatory diseases represent a challenging space for drug discovery due to the difficulty of delivering drugs to these privileged compartments
- While degraders typically fall well outside the established chemical “rules” for predicting CNS penetration, Nurix’ approach to optimization has allowed us to develop a portfolio of CNSpenetrant degraders with demonstrated activity in animal models and in the clinic
- Targeted protein degradation represents a powerful therapeutic strategy that can address privileged compartments, disrupt pathogenic scaffold functions and target previously undruggable proteins
